Over the past five months, you've taken many important steps. Some of them may not have been easy. But you've stayed with it. You can feel good about how far you've come.
As you continue to move forward, your Here to Help® Team is here to help you stay motivated, set new goals, and track your progress so you can let your doctor and your counselor know.
| You should know: SUBOXONE Film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and support. |
Supporting you, supporting your progress
 | Help yourself to these tools |
|
| Use your Here to Help toolbox to help you find motivation, set goals, plan for success, and think ahead, all in support of your treatment goals. These tools are meant to be used together—and returned
to often. Open Your Toolbox Now |
|
| Find your motivation |
|
| What motivates you to get up in the morning—and stay in treatment? Is it your family, your own expectations, your job, or something else? Whatever it is, name it, understand it, and keep it present in your thinking. Find Motivation Now |
|
| Watch small goals lead to big results |
|
| Remember, the larger goal of treatment success is made up of many smaller ones. Download the Here to Help Setting Goals Tool for extra help creating specific, realistic, achievable goals. |
|
Celebrating your accomplishments, small and large—we're here to help.
Take care,
866-973-HERE (4373)
|
|
Important Safety Information
SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.
SUBOXONE Sublingual Film should not be used by patients hypersensitive to buprenorphine or naloxone.
SUBOXONE Sublingual Film can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.
Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.
SUBOXONE Sublingual Film can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film. Dose reduction of CNS depressants, SUBOXONE Sublingual Film, or both when both are being taken should be considered.
Liver function should be monitored before and during treatment.
Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.
Children who take SUBOXONE Sublingual Film can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film out of the sight and reach of children.
Intravenous misuse or taking SUBOXONE Sublingual Film before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.
Neonatal withdrawal has been reported. Use of SUBOXONE Sublingual Film in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk. Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.
Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are numb mouth, sore tongue, redness of the mouth, headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, swelling of the limbs, disturbance of attention, palpitations, and blurred vision.
Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.
This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film. Please see full Product Information for a complete list.
To report an adverse event associated with taking SUBOXONE Sublingual Film, please call 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Product information and Medication Guide for Suboxone Film
For more about SUBOXONE Tablet, please see full Product Information
|
|
Unsubscribe | Privacy Promise | Terms of Use | Product Information
If you don't want to get e-mail communications from us in the future, you can opt out.
This communication is sponsored by Reckitt Benckiser and intended for residents of the United States.
SUBOXONE® and Here to Help® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.
SUBOXONE Film is manufactured for Reckitt Benckiser
Pharmaceuticals Inc., Richmond, VA 23235 by
MonoSol RX LLC, Warren, NJ 07059.
Copyright © 2010 Reckitt Benckiser Pharmaceuticals Inc.
Reckitt Benckiser Pharmaceuticals Inc.
10710 Midlothian Turnpike
Richmond, VA 23235-4722
The information in this e-mail is provided for educational and informational purposes only and is not intended as a substitute for direct consultation with a qualified health professional.
|
|
